Cogent Biosciences (COGT) Other Non-Current Liabilities (2020 - 2026)
Cogent Biosciences (COGT) posted quarterly Other Non-Current Liabilities of $62000.0 for Q1 2026, up 1140.0% year-over-year from $5000.0 in Q1 2025, and up 87.88% quarter-over-quarter from $33000.0 in Q4 2025.
Cogent Biosciences (COGT) Other Non-Current Liabilities (2020 - 2026) Analysis & Trends
Cogent Biosciences (COGT) has reported Other Non-Current Liabilities for 5 consecutive years, with $62000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Other Non-Current Liabilities rose 1140.0% year-over-year to $62000.0; the TTM figure through Mar 2026 stood at $62000.0 (up 1140.0% YoY), while the FY2025 annual figure was $33000.0, changed N/A from the prior year.
- Other Non-Current Liabilities advanced to $62000.0 in Q1 2026 per COGT's latest filing, from $33000.0 in the prior quarter.
- Across five years, Other Non-Current Liabilities topped out at $2.4 million in Q3 2025 and bottomed at $5000.0 in Q1 2025.
- Historically, Other Non-Current Liabilities has averaged $1.1 million across 3 years, with a median of $881000.0 in 2022.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities tumbled 44.44% — and 2026, when it jumped 1140.0%.
- Cogent Biosciences' Other Non-Current Liabilities stood at $1.7 million in 2022, then sank by 98.06% to $33000.0 in 2025, then jumped by 87.88% to $62000.0 in 2026.
- Business Quant data shows COGT's Other Non-Current Liabilities at $62000.0 in Q1 2026, $33000.0 in Q4 2025, and $2.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90,000.00 |
| Mar 31, 2026 | 62,000.00 |
| Dec 31, 2025 | 33,000.00 |
| Sep 30, 2025 | 2.37 Mn |
| Jun 30, 2025 | 2.36 Mn |
| Mar 31, 2025 | 5,000.00 |
| Dec 31, 2022 | 1.70 Mn |
| Dec 31, 2021 | 3.06 Mn |
| Dec 31, 2020 | 5.53 Mn |